What Diclofenac Labesfal Treats: Main Uses and Benefits

Diclofenac Labesfal is used in situations involving certain distressing symptoms across multiple clinical domains where symptoms related to physical discomfort, swelling, and functional stability are primary concerns. Its therapeutic applications are directed toward the management of various inflammatory and painful conditions. The medication’s benefit contributes to easing the overall symptom burden, may help patients cope more steadily with difficult episodes, and supports improved day-to-day comfort.

The medicine is commonly used across conditions presenting with acute episodes and recurrent manifestations, including chronic inflammatory joint issues like osteoarthritis and rheumatoid arthritis, specific pain syndromes such as acute migraine attacks and primary dysmenorrhea, and discomfort following post-traumatic injuries or postoperative procedures. It assists in addressing symptom clusters that may become intense or disruptive, such as joint pain, chronic stiffness, and local swelling.

“This medicine is relevant when supportive symptom management is appropriate, especially during phases when symptoms become more noticeable.”

---

QuickFact

Quick Fact: Relief for Key Symptoms
Supports easing pain and stiffness in chronic joint disorders.
May assist with managing pronounced symptoms during acute flare-ups (e.g., gout).
Contributes to temporary assistance in symptom stabilization during episodic pain events.

Regulatory References

1. NIH StatPearls overview

Official Eligibility and Non-Eligibility for Diclofenac

Regulatory documents strictly define who must not use diclofenac due to severe health risks. Use is allowed only in patients who do not possess these contraindications and is generally restricted to the lowest effective dose for the shortest duration possible.

Contraindicated Populations	Condition-Specific Restrictions
Patients with known hypersensitivity to diclofenac, aspirin, or other NSAIDs (e.g., if they precipitate asthma or urticaria).	Severe Hepatic or Renal Impairment (Failure) is an absolute contraindication.
Individuals with active gastrointestinal (GI) ulceration, bleeding, or perforation.	Established Cardiovascular Disease, including Congestive Heart Failure (NYHA Class II-IV), Ischemic Heart Disease, and Cerebrovascular Disease.
Patients recovering from Coronary Artery Bypass Graft (CABG) surgery.	Last Trimester of Pregnancy (starting at approximately 30 weeks gestation) is contraindicated.

Age-Related Eligibility: Diclofenac is generally not recommended for children and adolescents under 14 years for specific formulations due to dosage strength, and its safety has not been established in all pediatric groups. The elderly require particular caution, with regulatory labels recommending the lowest effective dose for the shortest time, especially for frail patients.

Restricted Use: Caution is mandatory for patients with mild to moderate hepatic or renal impairment, a history of GI issues (like Crohn’s disease), and those with cardiovascular risk factors (e.g., hypertension). Use is not recommended in breastfeeding women.

Interactions with other medicines and products

Regulatory documents define the interaction profile of Diclofenac Labesfal based on official warnings regarding pharmacodynamic and pharmacokinetic effects with co-administered substances. The medication is formally contraindicated for the treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) Surgery.

---|--- Medicines with Pharmacodynamic Interaction | Documented Outcome Other NSAIDs, Anticoagulants, Antiplatelet agents, and SSRIs | Significantly increased risk of serious bleeding events and gastrointestinal ulceration. Diuretics, ACE-inhibitors, and ARBs | Officially documented to diminish the therapeutic effect and increase the risk of renal toxicity, particularly in the elderly or volume-depleted patients.

---|--- Medicines with Pharmacokinetic Interaction | Documented Outcome Lithium and Methotrexate | Co-administration increases the plasma concentration of these drugs by reducing their renal clearance, enhancing the risk of toxicity. Potent CYP2C9/3A4 Inhibitors (e.g., Voriconazole) | Documented to significantly increase the exposure (plasma levels) of Diclofenac itself by inhibiting its metabolism.

Consumption of alcohol is officially documented to increase the risk of serious gastrointestinal bleeding. For certain oral forms, administration with food can result in reduced effectiveness due to altered absorption, a documented drug-food interaction.

How Diclofenac Labesfal Works

Inhibiting Prostaglandin Synthesis

The core mechanism involves the reversible inhibition of Cyclooxygenase (COX) enzymes, particularly COX-2, which are essential for producing chemical messengers called prostaglandins. Diclofenac blocks the enzyme's active site, interrupting the arachidonic acid cascade and significantly reducing the local concentration of Prostaglandin E2 (PGE2). This molecular interference limits the chemical signal cascade that drives vasodilation and increased tissue permeability, resulting in modulation of the local inflammatory response and reduction of the hypothalamic temperature setpoint.

---

Non-COX Modulation of Pain Signaling

Beyond enzyme inhibition, the drug engages secondary, non-prostaglandin-related mechanisms. Diclofenac is applied to adjust activity within peripheral pathways by modulating ion channels on nerve endings, such as acid-sensing ion channels (ASICs) and neuronal potassium channels. This interaction limits the impact of excessive chemical stimulation on the nerve itself, contributing to localized modulation of nociceptive signal transmission that is mechanistically independent of the inflammatory response.

---

⏳ Sustained Tissue-Level Modulation

Diclofenac achieves and maintains a high inhibitory concentration directly in inflamed tissues, such as the synovial fluid of joints, rather than just relying on systemic blood plasma levels. This sustained presence allows for prolonged, targeted inhibition of COX at the primary source of inflammatory mediator production. This mechanism facilitates sustained local anti-inflammatory modulation at the primary site of mediator production.

Official Administration Guidelines

Administration of Diclofenac Labesfal, which utilizes the active ingredient Diclofenac, is based on the principle of employing the lowest effective dosage for the shortest duration possible. The medicine is available in various forms, allowing for multiple approved routes, including oral (tablets, capsules, powder), parenteral (intramuscular and intravenous injection), rectal (suppositories), and topical preparations.

For most systemic uses in adults, the general maximum daily dose is 150 mg; however, standard regimens for conditions such as rheumatoid arthritis may be dosed up to 200 mg daily in divided amounts. Prolonged-release oral forms are designed for once-daily use, while immediate-release tablets are typically taken in divided doses (e.g., two to four times daily).

Specific administration rules govern how the form is ingested or prepared. Delayed-release or extended-release tablets must be swallowed whole without being crushed or chewed. While some oral forms may be taken with food, certain immediate-release capsules or oral powder for solution should be taken on an empty stomach for optimal effect. The oral powder must be mixed with a measured amount of water (e.g., 30 to 60 mL) and consumed immediately.

Parenteral use (IM/IV) is generally restricted to a short duration, such as a maximum of two days, with treatment not to exceed 150 mg in 24 hours. Intravenous infusion requires prior dilution and buffering with specified solutions and must not be administered as a rapid bolus. Dosing recommendations for older adults and those with mild to moderate kidney or liver function impairment often prioritize the initiation of the lowest effective dose.

Research Evidence / Overview of Studies for Diclofenac Labesfal

---

Evidence for use in Inflammatory Joint Conditions (e.g., Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis)

Research has explored the use of Diclofenac Labesfal in conditions marked by functional limitations and outcomes reflecting daily functioning or activity level, specifically in adults with various forms of arthritis. The body of evidence includes Randomized Controlled Trials (RCTs) and various comprehensive research summaries. These studies focused on measuring outcomes related to physical discomfort, such as joint pain, stiffness, and swelling.

Research highlights changes measured during the study period, which were often short-term, typically ranging up to three months. Findings describe patterns observed in the studies related to a shift in patient-reported pain scores compared to inactive treatments. Evidence contributes to understanding symptom patterns in conditions characterized by fluctuating manifestations.

---

Evidence for use in Acute Pain and Inflammation (e.g., Post-Traumatic Pain, Menstrual Cramps)

Diclofenac Labesfal was studied in research exploring short-term symptom changes describing episodic or acute changes, such as pain following surgery, injury, or menstrual cramps. These research scenarios primarily involve short-term, single-dose or very short-course RCTs. The studies monitored the time until patients reported a shift in pain intensity and the use of supplemental medication. Findings describe patterns observed in these studies, indicating that for certain formulations, changes in acute pain were measured during the observed time intervals.

---

What is Still Uncertain About Diclofenac Labesfal

Comparative evidence is lacking for many direct head-to-head comparisons against other available treatments. Follow-up durations were limited across the primary efficacy studies, so the long-term effects and durability of observed changes are not fully established. Additionally, data for certain groups, including children or those with complex, pre-existing health conditions, remain insufficient. Research is ongoing to better understand these evidence gaps and to provide clearer context for patient experiences.

Key Studies & References Clinical Guideline: NICE Guideline for the management of osteoarthritis

Common questions about Diclofenac Labesfal (FAQ)

Q: How quickly does Diclofenac Labesfal typically start to work?

A: Official information suggests that changes in patient symptoms may be observed within one week for conditions like arthritis, according to studies and product information. However, it can take several weeks to experience the full, sustained effect.

Q: What is the expected length of time that the effects of Diclofenac Labesfal last?

A: The duration of the effect is dependent on the specific formulation of the medicine. Immediate-release forms are often taken two to three times per day, while some slow-release forms may be scheduled to be taken 10 to 12 hours apart.

Q: What is the standard recommended frequency of use for Diclofenac Labesfal?

A: For immediate-release oral tablets or capsules, the standard frequency is often described in product labeling as 2 to 3 times per day. The specific frequency, however, is always determined by the dosage and the exact formulation provided.

Q: Are there specific instructions for what to do if a dose of Diclofenac Labesfal is missed?

A: Regulatory guidance advises that if a dose is missed, it should be taken as soon as you remember, unless it is nearly time for your next scheduled dose, in which case the missed dose should be skipped. Taking a double dose is generally advised against.

Q: Do health professionals generally view Diclofenac Labesfal as a long-term or short-term treatment?

A: Official guidance universally emphasizes that Diclofenac should be used for the shortest duration possible necessary to control symptoms. This preference for short-term use is documented due to the increase in potential risks associated with longer treatment durations.

Q: Is Diclofenac Labesfal safe for use in older adults?

A: Official guidance emphasizes that use in the elderly requires particular caution and often prioritizes the use of the lowest effective dose for the shortest duration. This is because older adults are documented to be at increased risk for serious adverse events, particularly cardiovascular and gastrointestinal complications.

Q: What information is available regarding the use of Diclofenac Labesfal during pregnancy?

A: According to regulatory documents, use during the last trimester of pregnancy (starting at about 30 weeks gestation) is strictly contraindicated due to documented risks to the fetus. Use in the first and second trimesters is advised to be handled with caution.

Q: Are there warnings about driving or operating machinery while on Diclofenac Labesfal?

A: Yes, official warnings advise that patients should avoid driving or operating machinery if they experience certain side effects, such as dizziness, vertigo (a spinning sensation), or visual disturbances, as these effects can impair ability.

Q: Can Diclofenac Labesfal be used by people with asthma?

A: Diclofenac is formally contraindicated (not permitted) in patients with known hypersensitivity to NSAIDs, aspirin, or diclofenac itself if these substances have been known to precipitate conditions like asthma.

Q: Does Diclofenac Labesfal have a history of recalls or safety updates?

A: Yes, regulatory bodies have issued safety updates over time, including the reclassification of certain oral diclofenac products to prescription-only status in some regions. These actions are documented and often relate to concerns regarding cardiovascular risk.

Q: Can Diclofenac Labesfal be used for headaches?

A: Diclofenac is officially indicated and used for the treatment of acute migraine attacks in adults. It is important to note that it is used to treat an existing attack, not to prevent or lessen the overall frequency of migraines.

Q: Is a stomach ache a common issue when taking Diclofenac Labesfal?

A: Yes, abdominal pain, which covers the intent of a stomach ache, is listed as a common adverse reaction in official product information, along with nausea and dyspepsia (indigestion).

Q: Is it normal to feel drowsy after taking Diclofenac Labesfal?

A: Drowsiness and somnolence (sleepiness) are documented as possible nervous system side effects in the regulatory product information for diclofenac.

Q: Is it possible for Diclofenac Labesfal to cause swelling in the ankles or feet?

A: Yes, fluid retention and edema (swelling) are documented as reported adverse effects associated with the use of NSAIDs. This swelling is often noticed in the ankles or feet.

Q: Why do some people report feeling dizzy when using this medicine?

A: Dizziness is a documented adverse effect. Official product information notes that the drug's mechanism of action may be linked to effects on the central nervous system and potential changes in blood pressure and vascular tone, which are possible causes of this symptom.

Q: Has Diclofenac Labesfal been linked to liver function changes?

A: Yes, regulatory information documents that elevated liver enzyme levels (transaminases) are a common adverse reaction. More severe hepatic (liver) reactions are classified as uncommon or rare.

Q: Can Diclofenac Labesfal cause skin reactions or a rash?

A: Yes, a rash is listed as a common adverse reaction in official safety documents. Less common but very severe skin reactions, such as Stevens-Johnson Syndrome, are also documented.

Q: Does Diclofenac Labesfal affect sleep?

A: Yes, the use of diclofenac is associated with documented nervous system side effects that may potentially affect sleep patterns, including reports of insomnia and dream abnormalities.

Q: Is Diclofenac Labesfal known to cause dry mouth?

A: Dry mouth is listed as a possible adverse effect on the digestive system in the regulatory product information for diclofenac.

Q: Is Diclofenac Labesfal an opioid?

A: No. Diclofenac Labesfal is definitively classified as a Non-steroidal Anti-inflammatory Drug (NSAID). This classification confirms it is not an opioid medicine and does not act on the body in the same way.

Q: Does Diclofenac Labesfal have a risk of addiction?

A: As Diclofenac is classified as a Non-steroidal Anti-inflammatory Drug (NSAID) and is not an opioid, it is not associated with the risk of addiction that is documented for controlled substance medicines like opioids.

Q: Are there different strengths or formulations of Diclofenac Labesfal?

A: Yes, the active ingredient diclofenac is manufactured in numerous dosage forms, including oral tablets, capsules, topical gels, and suppositories. These come in different strengths and release characteristics, such as immediate-release and slow-release.

Q: What does the name 'Labesfal' refer to in the drug name?

A: The term 'Labesfal' is the specific brand name or trade name used to identify this particular manufacturer's pharmaceutical preparation containing the active ingredient diclofenac.

Q: Does Diclofenac Labesfal contain lactose or other common allergens?

A: The inactive ingredients (excipients) vary significantly by product formulation and brand. Regulatory documents for some specific oral tablet forms confirm they do contain common excipients like lactose.

Q: Are there any specific laboratory tests that might be affected by Diclofenac Labesfal?

A: Yes, the regulatory documents state that the medicine can affect lab results. Specifically, elevated liver enzyme levels (transaminases) are a common adverse reaction. Other tests that may be affected include certain blood counts like hemoglobin and hematocrit.

Q: Does taking Diclofenac Labesfal interact with blood thinning medicines?

A: Yes, regulatory documents define a significantly increased risk of serious bleeding events and gastrointestinal ulceration when diclofenac is taken with anticoagulants and antiplatelet agents, which are common blood thinning medicines.

Q: Does Diclofenac Labesfal interact with antidepressants?

A: Diclofenac is documented to interact with Selective Serotonin Reuptake Inhibitors (SSRIs), which is a major class of antidepressants. This interaction is associated with a documented potential for an increased risk of serious bleeding events.

Q: Are there any specific foods or drinks to avoid while using Diclofenac Labesfal?

A: Official warnings document that consumption of alcohol is directly linked to an increased risk of serious gastrointestinal bleeding when taken with diclofenac.

Q: Does Diclofenac Labesfal interact with common over-the-counter supplements?

A: Regulatory agencies generally note that there is insufficient data available regarding the safety of taking herbal remedies, supplements, and other complementary medicines alongside diclofenac.

Q: Is it known if Diclofenac Labesfal affects blood pressure?

A: Yes, the use of NSAIDs, including diclofenac, is officially associated with the potential for the new onset or the worsening of pre-existing hypertension (high blood pressure), according to official safety documentation.

Storage Requirements

The required storage conditions for Diclofenac are dependent on the specific formulation. Diclofenac prolonged-release tablets and suppositories must be stored below 25 C. In contrast, Diclofenac topical gel does not require special temperature conditions but must be kept in the original tube to protect from light. All forms of the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Disposal must be completed in accordance with local requirements for pharmaceutical waste. Regulatory information explicitly notes that Diclofenac poses a risk to the aquatic environment, and the product must not be thrown into wastewater. Any unused or expired medicine should be handled to prevent environmental contamination.